Sun Pharmaceutical Industries has announced that it has began Phase II clinical trial on AQCH, a phytopharmaceutical (plant derived) drug for treatment of COVID-19. The Company acquired approval from the Drugs Controller General of India (DCGI) for conducting Phase II scientific trial in April this yr.
The medical trial could be carried out across 12 facilities in India in 210 patients. The treatment duration for sufferers can be 10 days. The consequences of the clinical trial are anticipated through October 2020. Human safety study of AQCH has already been completed and the drug has been determined secure at the advocated dose for Phase II look at.
Bazaarinformation team has many years of experience, covering the physical and future commodities markets with prominent commodity & equity trading advising which shines further with extensive network to get research from ground levels to generate proper reporting and movements. We are able to get evens out of odds in volatile markets and stockings. ...
